5月9日,复星医药(600196/02196)发布公告,控股子公司菌济健康获得美国FDA关于LBP-ShC4开展临床试验的批准。该产品为公司自主研发的活体生物治疗产品,旨在治疗雄激素脱发(AGA)。截至2025年4月,公司在LBP-ShC4的研发上累计投入约为0.17亿元(未经审计)。公告指出,目前全球尚无用于治疗雄激素脱发的活体生物治疗产品获批上市。尽管获得临床试验批准,但药品研发存在风险,后续...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.